Bioresponsive Particles

Abstract

Shielding enzymes are made by modifying the enzyme surface with silica precursors and then depositing silica to a desired thickness while retaining biological activity of the enzyme.

Description

[0001]Priority: This application claims priority to Ser No. 62 / 679,762, filed: Jun. 01, 2018.[0002]This invention was made with government support under Grant Number UL1TR001105 awarded by the National Institutes of Health (NIH). The government has certain rights in the invention.INTRODUCTION[0003]Acute lymphoblastic leukemia (ALL) is the most common childhood cancer accounting for more than 25 percent of all pediatric cancers in the U.S. Unfortunately, 30 percent of children have immune responses to one of the most effective treatments for ALL that is highly allergenic. These immune responses either render the treatment completely ineffective, particularly when children relapse, or worse, immediately threaten the life of the child, or both. Because this treatment is essential for permanently curing children of ALL, it is critical that novel strategies be devised to completely eliminate these immune reactions.[0004]In an aspect, our invention provides for incorporating this treatmen...

AI Technical Summary

Benefits of technology

The invention provides a way to protect children from harmful immune responses while still effectively treating cancer. This is done by creating ultra-small particles that can safely deliver the treatment enzyme and deplete asparagine, which is important for cancer cells. The patent also allows for continuous fine-tuning of enzyme activity per particle and particle size. This provides full control over the number of enzyme molecules per particle and particle size.

Problems solved by technology

These immune responses either render the treatment completely ineffective, particularly when children relapse, or worse, immediately threaten the life of the child, or both.

The second approach has particle size and enzyme loading limitations.

This relatively large size forces them to stay in blood speeding their removal by the liver and spleen, and limiting their ability to reach the cellular microenvironment in sufficient quantities to adequately fight cancer or provide enzymes to cells that so desperately need them.

Further, since they are filled by suspending them in aqueous solutions of the enzyme, they can only trap the amount that can be dissolved without precipitation limiting enzyme loading.

Low enzyme activity requires higher dosages to achieve the enzyme activity needed for the desired application, increasing toxicity.

Images